Anti-Giardia lamblia IgM is an early immunological marker of infection caused by Giardia lamblia (also known as G. duodenalis or G. intestinalis), a protozoan parasite responsible for giardiasis, one of the most common intestinal parasitic infections worldwide. During acute infection, the host immune system produces IgM antibodies as part of the primary humoral response against Giardia antigens, often appearing before IgG and IgA antibodies. The presence of specific IgM antibodies can therefore serve as an indicator of recent or ongoing infection, distinguishing acute giardiasis from past or chronic exposure.
In clinical settings, detection of Human Anti-Giardia lamblia IgM is valuable for diagnostic assays, particularly serological ELISA tests, to complement stool microscopy or antigen-based detection methods. Since IgM appears early in the course of infection, it can help identify newly acquired giardiasis cases, support differential diagnosis of gastrointestinal symptoms, and assist in epidemiological surveillance where stool samples may be difficult to obtain or inconclusive.
In research applications, Human Anti-Giardia lamblia IgM is used as a biomarker to study host-parasite interactions, immune responses in early infection, and the kinetics of antibody production during protozoan infections. It also provides a useful tool for validating diagnostic platforms, developing reference standards, and evaluating vaccine candidates or therapeutic interventions. By monitoring IgM responses, researchers can better understand the immunopathology of giardiasis and assess immune protection following experimental exposure or treatment.
This product is manufactured in USA by Eagle Biosciences.
